DT 2219ARL

Drug Profile

DT 2219ARL

Alternative Names: Anti-CD19-anti-CD22-diphtheria-toxin-fusion-protein; DT-2219ARL; DT2219; IND100780; OXS 1550

Latest Information Update: 25 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Minnesota
  • Class ADP ribose transferases; Antineoplastics; Bispecific antibodies; Drug conjugates; Immunotoxins; Recombinant fusion proteins
  • Mechanism of Action Immunomodulators; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II B cell lymphoma; Leukaemia

Most Recent Events

  • 18 Apr 2017 Phase-II clinical trials in B-cell lymphoma (Second-line therapy or greater) in USA (IV) (NCT02370160)
  • 18 Apr 2017 Phase-II clinical trials in Leukaemia (Second-line therapy or greater) in USA (IV) (NCT02370160)
  • 31 Mar 2017 Oxis Biotech has patent protection for DT 2219ARL covering methods and compositions for bi-specific targeting of cd19/cd22 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top